A new analysis of clinical trial results shows that Merck’s antiviral pill for treating COVID-19 is significantly less effective than previously reported in October, the company announced on Friday.
In the updated report, the drugmaker said its antiviral treatment drug, which is called molnupiravir, showed a 30 percent reduction in hospitalizations and deaths from the CCP (Chinese Communist Party) virus, based on data from 1,433 patients.
